Pharmacogenetics of methotrexate in patients with rheumatoid arthritis

Masayuki Hashiguchi, Mayumi Mochizuki

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory disorder that mainly affects the joints. Despite the availability of the new biological agents such as TNF-blocking agents, methotrexate (MTX) remains as the primary agent for the treatment of RA due to the low and broad experience with its use. The efficacy and adverse drug reactions of MTX are variable among patients, and this is partially contributed in genetic difference of drug-metabolizing enzymes, transporters, and receptors In this review, we described MTX pharmacogenetics that was related to a large interindividual variation on efficacy and adverse drug reactions in RA patients, including MTX transporter pharmacogenetics, MTX glutamation pharmacogenetics, folate pathway pharmacogenetics, and adenosine pathway pharmacogenetics. We also described the clinical implications between their pharmacogenetics and clinical outcomes (efficacy and/ or adverse drug reactions of MTX).

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume39
Issue number6
DOIs
Publication statusPublished - 2008 Nov

Fingerprint

Pharmacogenetics
Methotrexate
Rheumatoid Arthritis
Drug-Related Side Effects and Adverse Reactions
Biological Factors
Folic Acid
Adenosine
Joints
Enzymes
Pharmaceutical Preparations

Keywords

  • Methotrexate
  • Pharmacogenetics
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacogenetics of methotrexate in patients with rheumatoid arthritis. / Hashiguchi, Masayuki; Mochizuki, Mayumi.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 39, No. 6, 11.2008, p. 247-253.

Research output: Contribution to journalArticle

@article{0e5c848670b2456abd3d9d75505d509e,
title = "Pharmacogenetics of methotrexate in patients with rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a systemic inflammatory disorder that mainly affects the joints. Despite the availability of the new biological agents such as TNF-blocking agents, methotrexate (MTX) remains as the primary agent for the treatment of RA due to the low and broad experience with its use. The efficacy and adverse drug reactions of MTX are variable among patients, and this is partially contributed in genetic difference of drug-metabolizing enzymes, transporters, and receptors In this review, we described MTX pharmacogenetics that was related to a large interindividual variation on efficacy and adverse drug reactions in RA patients, including MTX transporter pharmacogenetics, MTX glutamation pharmacogenetics, folate pathway pharmacogenetics, and adenosine pathway pharmacogenetics. We also described the clinical implications between their pharmacogenetics and clinical outcomes (efficacy and/ or adverse drug reactions of MTX).",
keywords = "Methotrexate, Pharmacogenetics, Rheumatoid arthritis",
author = "Masayuki Hashiguchi and Mayumi Mochizuki",
year = "2008",
month = "11",
doi = "10.3999/jscpt.39.247",
language = "English",
volume = "39",
pages = "247--253",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "6",

}

TY - JOUR

T1 - Pharmacogenetics of methotrexate in patients with rheumatoid arthritis

AU - Hashiguchi, Masayuki

AU - Mochizuki, Mayumi

PY - 2008/11

Y1 - 2008/11

N2 - Rheumatoid arthritis (RA) is a systemic inflammatory disorder that mainly affects the joints. Despite the availability of the new biological agents such as TNF-blocking agents, methotrexate (MTX) remains as the primary agent for the treatment of RA due to the low and broad experience with its use. The efficacy and adverse drug reactions of MTX are variable among patients, and this is partially contributed in genetic difference of drug-metabolizing enzymes, transporters, and receptors In this review, we described MTX pharmacogenetics that was related to a large interindividual variation on efficacy and adverse drug reactions in RA patients, including MTX transporter pharmacogenetics, MTX glutamation pharmacogenetics, folate pathway pharmacogenetics, and adenosine pathway pharmacogenetics. We also described the clinical implications between their pharmacogenetics and clinical outcomes (efficacy and/ or adverse drug reactions of MTX).

AB - Rheumatoid arthritis (RA) is a systemic inflammatory disorder that mainly affects the joints. Despite the availability of the new biological agents such as TNF-blocking agents, methotrexate (MTX) remains as the primary agent for the treatment of RA due to the low and broad experience with its use. The efficacy and adverse drug reactions of MTX are variable among patients, and this is partially contributed in genetic difference of drug-metabolizing enzymes, transporters, and receptors In this review, we described MTX pharmacogenetics that was related to a large interindividual variation on efficacy and adverse drug reactions in RA patients, including MTX transporter pharmacogenetics, MTX glutamation pharmacogenetics, folate pathway pharmacogenetics, and adenosine pathway pharmacogenetics. We also described the clinical implications between their pharmacogenetics and clinical outcomes (efficacy and/ or adverse drug reactions of MTX).

KW - Methotrexate

KW - Pharmacogenetics

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=58849157687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849157687&partnerID=8YFLogxK

U2 - 10.3999/jscpt.39.247

DO - 10.3999/jscpt.39.247

M3 - Article

AN - SCOPUS:58849157687

VL - 39

SP - 247

EP - 253

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 6

ER -